Bone and bone derived factors in kidney disease

Purpose of review: Mineral and bone disorder (MBD) is a prevalent complication in chronic kidney disease (CKD), significantly impacting overall health with multifaceted implications including fractures, cardiovascular events, and mortality. Despite its pervasive nature, effective treatments for CKD-...

Full description

Bibliographic Details
Published in:	Frontiers in Physiology
Main Author:	Petra Simic
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	renal osteodystrophy CKD-MBD mineral and bone disorder CKD FGF23 = fibroblast growth factor 23
Online Access:	https://www.frontiersin.org/articles/10.3389/fphys.2024.1356069/full

Similar Items

The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort
by: Matthew J. Damasiewicz, et al.
Published: (2018-11-01)

Risk factors associated with disturbances of calcium homeostasis after initiation of a phosphate‐restricted diet in cats with chronic kidney disease
by: Pak‐Kan Tang, et al.
Published: (2021-01-01)

Cardiovascular Risk and Mineral Bone Disorder in Patients with Chronic Kidney Disease
by: Hagen Staude, et al.
Published: (2013-03-01)

Correlation of serum fibroblast growth factor-23 levels and calcium phosphate products levels in chronic kidney disease; sub analysis of chronic kidney disease-mineral and bone disorder study
by: Adeh Mahardika, et al.
Published: (2024-08-01)

Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
by: Yi-Chou Hou, et al.
Published: (2022-07-01)

Fracture Risk in Chronic Kidney Disease: Addressing an Overlooked Complication
by: Guido Gembillo, et al.
Published: (2025-07-01)

The Calcified Vasculature in Chronic Kidney Disease Secretes Factors that Inhibit Bone Mineralization
by: Maria L. Mace, et al.
Published: (2022-04-01)

Editorial: Management of osteoporosis in patients with chronic kidney disease
by: Mohamed Abdalbary, et al.
Published: (2023-01-01)

The importance of whey protein levels of Klotho and fibroblast growth of factor-23 (fgf-23) as early diagnostic markers of chronic kidney damage
by: L. Yu. Milovanova, et al.
Published: (2014-06-01)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
by: Hisato Shima, et al.
Published: (2018-06-01)

The Role of Daily Dialysate Calcium Exposure in Phosphaturic Hormones in Dialysis Patients
by: Francesca K. Martino, et al.
Published: (2024-07-01)

A potential link between fibroblast growth factor-23 and the progression of AKI to CKD
by: Yinghui Lu, et al.
Published: (2023-04-01)

Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double‐blind randomized controlled trial
by: Pak‐Kan Tang, et al.
Published: (2024-07-01)

Fibroblast growth factor 23 is independently associated with renal magnesium handling in patients with chronic kidney disease
by: Teodora V. Grigore, et al.
Published: (2023-01-01)

Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis
by: Armando Aguilar, et al.
Published: (2023-06-01)

Management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
by: Pringgodigdo Nugroho
Published: (2021-12-01)

Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients
by: Ahmed Fayed, et al.
Published: (2018-10-01)

Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects
by: Paolo Molinari, et al.
Published: (2022-03-01)

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
by: Megan L. Noonan, et al.
Published: (2020-06-01)

AMP‐dependent kinase stimulates the expression of αKlotho
by: Julia Vogt, et al.
Published: (2024-10-01)

Secondary and tertiary hyperparathyroidism in chronic kidney disease: An endocrine and renal perspective
by: Manju Chandran, et al.
Published: (2019-01-01)

Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis
by: Yao Liu, et al.
Published: (2025-02-01)

In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study
by: Meizi Kang, et al.
Published: (2022-06-01)

Bone fragility in patients with chronic kidney disease
by: Martine Cohen-Solal, et al.
Published: (2020-04-01)

Fractures in patients with chronic kidney disease
by: S. L. Dudar
Published: (2021-08-01)

Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?
by: Lara Caldiroli, et al.
Published: (2025-04-01)

Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease
by: Jennifer Peugh, et al.
Published: (2019-07-01)

Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease
by: Rupinder Kaur, et al.
Published: (2023-10-01)

Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
by: Daniel Cejka
Published: (2021-11-01)

New biomarkers of bone remodelling regulation in patients with acromegaly and endogenous hypercortisolism
by: Timur T. Tsoriev, et al.
Published: (2018-10-01)

The Role of ADMA as an Indicator of Progression in Early Stage of CKD
by: Satriyo Dwi Suryantoro, et al.
Published: (2025-09-01)

Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder
by: Maria P. Yavropoulou, et al.
Published: (2020-12-01)

Chronic Kidney Disease (CKD) as a Systemic Disease: Whole Body Autoregulation and Inter-Organ Cross-Talk
by: Carmine Zoccali, et al.
Published: (2014-07-01)

Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM)
by: José-Vicente Torregrosa, et al.
Published: (2023-06-01)

Risk factors and implications associated with ultrasound‐diagnosed nephrocalcinosis in cats with chronic kidney disease
by: Pak‐Kan Tang, et al.
Published: (2024-05-01)

Advances in Metabolic Reprogramming of Osteoblasts with the Development of Early Renal Bone Disease
by: WANG Zuoyu, ZHOU Yang, XIONG Mingxia, ZHAO Shasha, YANG Junwei
Published: (2024-05-01)

Comparison of control status and influencing factors of serum calcium, phosphorous and parathyroid hormone between peritoneal and hemodialysis patients
by: Chu Rui, et al.
Published: (2021-01-01)

Association between Allelic Variations of -174G/C Polymorphism of Interleukin-6 Gene and Chronic Kidney Disease-Mineral and Bone Disorder in Iraqi Patients
by: Mohanad Radeef
Published: (2020-12-01)

Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)
by: Sho Shimamoto, et al.
Published: (2024-11-01)

The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
by: Giuseppe Cianciolo, et al.
Published: (2020-06-01)